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Pulmonary ultrasound is a useful tool in the diagnosis and resuscitation of emergency
department (ED) patients with dyspnea. We present the case of a patient who was
diagnosed with E-cigarette or vaping product use-associated lung injury (EVALI) using
pulmonary ultrasound. Many of these cases are diagnosed using x-ray, computerized
tomography, or bronchoscopy and to our knowledge this is the first published case
that demonstrates utility of ultrasound in diagnosing EVALI. While more investigation
is needed on the use of this technique, the patient in this case was diagnosed with
EVALI based on positive history, presence of normal cardiac function, non-cardiogenic
pulmonary edema on ultrasound, and absence of pulmonary infection.
1 INTRODUCTION
E-cigarette use, or vaping, is increasingly prevalent as a modality for
tobacco and tetrahydrocannabinol (THC) consumption. The long-term
effects of electronic cigarette use are not yet known due to its rel-
ative infancy, but E-cigarette or vaping product use-associated lung
injury (EVALI) has become a recognized condition. EVALI is a spectrum
of disease that includes diffuse alveolar hemorrhage, lipoid pneumo-
nia, acute eosinophilic pneumonia, hypersensitivity pneumonitis, and
organizing pneumonia.1,2 Patients may present to the hospital with
a myriad of symptoms that can include dyspnea, cough, chest pain,
exercise intolerance, gastrointestinal upset and interventions required
may range from simple monitoring to supplemental oxygen admin-
istration, mechanical ventilation, extracorporeal membrane oxygena-
tion, and lung transplant.3 Due to the diverse nature of complaints,
the differential diagnosis in these cases is broad and includes pneu-
monia, bronchitis, pulmonary edema secondary to cardiac or noncar-
diac causes, obstructive lung disease, pulmonary embolism, and acute
coronary syndrome. Diagnosis is made by clinical history and imaging
suggestive of lung injury. Imaging with chest x-ray and computerized
tomography (CT) scan can show ground glass opacities indicative of
lung injury and bronchoscopy can aid in diagnosis but to date there
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are no published reports of pulmonary ultrasound use in diagnosing
EVALI.4,5
2 CASE
A previously healthy 26-year-old male with a medical history of
exercise-induced asthma and e-cigarette use presented with dysp-
nea and cough for 9 days. The patient presented to the hospital in
November of 2019, before the Covid-19 pandemic. He was evaluated
at an urgent care where he was diagnosed with pneumonia and
placed on doxycycline. He remained symptomatic and was seen in
an outside hospital ED where azithromycin was added. Two days
prior to presentation to our ED he was again seen at urgent care and
given albuterol/ipratroprium nebulizer treatments, an intramuscular
dose of dexamethasone, and levofloxacin. One day prior to arrival he
developed blood-tinged sputum. His last use of e-cigarettes containing
THC was 5 days prior to arrival, though he reported over 1 year of
using THC-containing canisters.
On presentation to our ED, the patient was found to be hypox-
emic to 88% on room air and tachypneic. He was placed on 2L O2 by
nasal cannula with some improvement in symptoms and vital signs.
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F IGURE 1 Ultrasound of right lung apex demonstrates diffuse B lines indicating pulmonary edema
Pulmonary exam revealed diffuse rales with mild expiratory wheezes.
The differential diagnosis in this otherwise healthy patient with new
onset dyspnea, cough, and oxygen requirement included pneumonia,
bronchitis, asthma exacerbation, pneumothorax, pulmonary embolism,
heart failure, and cardiogenic pulmonary edema. Given the patient’s
history of e-cigarette use, EVALI was also considered.
Point-of-care ultrasound of the lungs and transthoracic echocardio-
gram were performed to evaluate the patient’s disease process. Bed-
side echocardiogram consisting of the standard subxiphoid, paraster-
nal long and short, IVC, and apical 4 chamber views showed a grossly
normal left ventricular ejection fraction (LVEF), no right heart strain,
and no pericardial effusion. Ultrasound of the lungs was performed
using the bedside lung ultrasound in emergency protocol and 6 views
were obtained.6 Views of the inferior and superior anterior lungs
and mid-thoracic posterior axillary line were obtained for a total of 6
images and diffuse B lines were visualized throughout all lung fields
(Figure 1). The presence of multiple B lines, or discrete hyperechoic
reverberation artifacts emanating from the pleural line and extending
into the lung parenchyma, indicated interstitial fluid.7 The patient had
appropriate lung sliding bilaterally, indicating the absence of a pneu-
mothorax. The posterior axillary line views showed no pleural effusion.
There was no evidence of pneumonia as the patient had no visualized
consolidations or air bronchograms and there was no hepatization of
the lungs.8 The presence of diffuse B-lines in conjunctionwith a normal
LVEF led to the diagnosis of diffuse noncardiogenic pulmonary edema.
The patient’s history of using THC-containing vape cartridges and evi-
dence of lung injury on imaging were consistent with EVALI. A CT scan
of the patient’s lungs confirmed the diagnosis (Figure 2).
The patient’s condition improved over the course of his hospitaliza-
tion.He received steroids andnebulizer treatments andwas eventually
F IGURE 2 CT scan of chest showing diffuse alveolar hemorrhage
weaned off supplemental oxygen. On discharge, the patient was able
to ambulate without oxygen while maintaining a normal oxygen sat-
uration. He was found to be negative for streptococcus pneumoniae,
legionella, influenza, RSV, HIV, hepatitis, and mycoplasma. A compre-
hensive respiratory viral panel was also negative. Sputum and blood
cultures were negative. A CT scan the day of discharge showed reso-
lution of his lung injury.
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3 DISCUSSION
Pulmonary edema, most likely secondary to diffuse alveolar hemor-
rhage, is a knowncomplicationof e-cigaretteuse.While there is no con-
sensus on a single cause of EVALI, the presence of vitamin E acetate
in THC oil-containing samples has been linked to lung injury.9 Surfac-
tant disruption by hydrophobic vitamin E likely results in lung injury,
causing non cardiogenic pulmonary edema. Despite having significant
lung injury and vital sign abnormalities, these patients often have nor-
mal exams by pulmonary auscultation. In this patient, use of ultrasound
helped diagnose EVALI by presence of B lines without any consolida-
tion, effusion, or pneumothorax.
Importantly, this patient had previously been diagnosed with pneu-
monia after chest x-rays at an urgent care and outside hospital. While
his symptoms of cough and dyspnea in the presence of an abnor-
mal chest x-ray were concerning for pneumonia, the patient did not
improve with antibiotics and fortunately continued to seek medical
care. Point-of-care lung ultrasound ultimately proved more valuable
in diagnosing his condition. The presence of B-lines on the patient’s
bedside ultrasound with appropriate lung sliding and lack of air bron-
chograms or hepatization indicated pulmonary edema rather than
pneumonia as the most likely diagnosis. As stated previously, the
absence of anechoic pleural effusions in the inferior thorax and the
presence of appropriate lung sliding excluded other potential causes of
the patient’s symptoms.
While EVALI represents a spectrum of disease, this patient’s par-
ticular injury resulted in the development of interstitial fluid and pul-
monary edema thatwas visible by ultrasound. Point-of-care ultrasound
is well recognized as a useful modality in dyspneic patients, and in
this patient with hypoxemia pneumothorax, effusion, consolidation,
and cardiogenic causes were quickly excluded. While auscultation and
chest x-ray can diagnose pulmonary edema, they alone are not suffi-
cient to determine its cause. Ultrasound was useful in diagnosing pul-
monary edema in this patient by demonstrating diffuse B lines without
evidence of other potential causes to the patient’s dyspnea. A point-of-
care echocardiogram showednormal ejection fraction, which indicated
anon-cardiogenic cause to this patient’s pulmonary edema.Ultrasound
findings identified the patient’s pathology and taken with a history
of E-cigarette use, the diagnosis of EVALI was confirmed. The patient
was therefore treatedwith steroids rather than diuretics or antibiotics
according to the current treatment recommendations for EVALI.10
4 CONCLUSION
EVALI represents a spectrumof diseasewith a broad range of symptom
severity. Pulmonary ultrasound is widely recognized as an important
aid in the evaluationof dyspneic EDpatients, and this case highlights its
utility in diagnosing this emerging disease. More research is needed to
determine its sensitivity in diagnosing EVALI and whether ultrasound
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